ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,917.11
0.00%
US Tech 100
20,094.00
-0.16%
Dow Jones
43,408.47
0.32%
Brent Oil
74.00
1.59%
Bitcoin
97,867.24
3.72%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Atossa Therapeutics Inc (ATOS) Quote

Atossa Therapeutics Inc

Atossa Therapeutics Inc (ATOS)

NASDAQ
1.20
-0.07
(-5.51%)
Closed November 20 4:00PM
Delayed by 15 minutes
1.17
-0.03
( -2.50% )
Pre Market: 6:40AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.17
Bid
1.16
Ask
1.17
Volume
851
0.00 Day's Range 0.00
0.70 52 Week Range 2.31
Market Cap
147.187M
Previous Close
1.20
Open
-
Last Trade
100
@
1.17
(formt)
Last Trade Time
06:40:28
Financial Volume
-
VWAP
-
Average Volume (3m)
584,439
Shares Outstanding
125,801,254
Dividend Yield
-
PE Ratio
-5.02
Earnings Per Share (EPS)
-0.24
Revenue
-
Net Profit
-30.09M

About Atossa Therapeutics Inc

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.atossatherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Atossa Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATOS. The last closing price for Atossa Therapeutics was $1.20. Over the last year, Atossa Therapeutics shares have traded in a share price range of $ 0.70 to $ 2.31.

Atossa Therapeutics currently has 125,801,254 shares outstanding. The market capitalization of Atossa Therapeutics is $150.96 million. Atossa Therapeutics has a price to earnings ratio (PE ratio) of -5.02.

Ask ADVFN Intelligence (AI)

ATOS Latest News

More News

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

22 hours ago
GlobeNewswire Inc.

Form 8-K - Current report

November 19 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

November 19 2024
Edgar (US Regulatory)

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key...

November 12 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 08 2024
Edgar (US Regulatory)

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice...

November 05 2024
GlobeNewswire Inc.

Form 8-K - Current report

November 04 2024
Edgar (US Regulatory)

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Atossa...

November 04 2024
GlobeNewswire Inc.

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial Low dose (Z)-endoxifen was well tolerated and...

October 31 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

October 22 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.22-15.82733812951.391.411.1710149641.27767719CS
4-0.28-19.31034482761.451.661.177341461.39705271CS
12-0.25-17.60563380281.421.661.175844391.42167796CS
26-0.42-26.41509433961.591.711.027108291.33733856CS
520.4358.10810810810.742.310.79406971.43119896CS
156-1.18-50.21276595742.352.450.510206021.29467965CS
260-0.1-7.874015748031.279.80.535420193.16527336CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 1.85
(88.78%)
14.78M
AKTSAkoustis Technologies Inc
$ 0.12985
(49.08%)
52.03M
PETWag Group Company
$ 0.312
(48.50%)
16.27M
CRKNCrown Electrokinetics Corporation
$ 1.13
(43.83%)
4.35M
ESGROEnstar Group Ltd
$ 28.00
(40.92%)
24
WSBFWaterstone Financial Inc
$ 9.00
(-40.98%)
4
TRSTriMas Corporation
$ 15.62
(-40.79%)
3
BCAXBicara Therapeutics Inc
$ 11.00
(-40.15%)
208
XNCRXencor Inc
$ 15.11
(-36.30%)
2
PYXSPyxis Oncology Inc
$ 2.44
(-36.13%)
201.93k
AKTSAkoustis Technologies Inc
$ 0.12985
(49.08%)
52.03M
PETWag Group Company
$ 0.312
(48.50%)
16.27M
WORXSCWorx Corporation
$ 1.85
(88.78%)
14.78M
XTKGX3 Holdings Company Ltd
$ 0.0797
(-11.44%)
10.59M
CRKNCrown Electrokinetics Corporation
$ 1.13
(43.83%)
4.35M

ATOS Discussion

View Posts
XenaLives XenaLives 3 months ago
Why on earth did it take me so long to find this?



Following...

https://x.com/stevenquay
👍️0
XenaLives XenaLives 3 months ago
I think I'm in love... LOL!!!



Historical perspective:

👍️0
XenaLives XenaLives 3 months ago
More interesting...

https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
XenaLives XenaLives 3 months ago
ATOS chart...

👍️0
XenaLives XenaLives 3 months ago
Interesting .. also from Google...

A response to this query...

what is unique about atossa therapeutics inc

Response...

Is Atossa Therapeutics a good buy?
Why is Atossa stock dropping?
Who owns Atossa Therapeutics?
What is the target price for Atossa Genetics?
Stock Price Target ATOS
High $6.25
Median $6.00
Low $4.00
Average $5.42
Current Price $1.39

ATOS | Atossa Therapeutics Inc. Analyst Estimates & Rating - WSJ

WSJ
https://www.wsj.com › quotes › ATOS › research-ratings
Search for: What is the target price for Atossa Genetics?
What is the stock price forecast for Atossa Therapeutics in 2025?
What does Atossa Therapeutics do?


👍️0
XenaLives XenaLives 3 months ago
From Google Generative AI:


Atossa Therapeutics is a clinical-stage biopharmaceutical company that develops innovative medicines for oncology, with a focus on breast cancer and other breast conditions. Some unique aspects of Atossa Therapeutics include:
Patented (Z)-endoxifen
Atossa has patented the chemical process and composition of matter for (Z)-endoxifen, as well as a patented oral enteric capsule formulation.
Phase 2 I-SPY 2 Clinical Trial
Atossa is fully enrolling this trial, which is evaluating (Z)-endoxifen as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive breast cancer.
Phase 2 trials
Atossa is currently studying (Z)-endoxifen in four Phase 2 trials, including one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and two other studies.
U.S. patents
Atossa's (Z)-endoxifen is protected by three issued U.S. patents and numerous pending patent applications.
👍️0
XenaLives XenaLives 3 months ago
Intriguing science...
👍️0
XenaLives XenaLives 3 months ago

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-00701&r=1
👍️0
XenaLives XenaLives 3 months ago
Link to Atossa pipeline...
https://atossatherapeutics.com/product-pipeline/
👍️0
XenaLives XenaLives 3 months ago
Following - some valid science is going on here...
👍️0
glenn1919 glenn1919 3 months ago
ATOS....................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ATOS.........................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 months ago
ATOS...............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 months ago
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️ 1
Joeyohso Joeyohso 7 months ago
Also no debt and 90m+ in cash. That is unheard of for a research pharma company. They also are extending the employee stock purchase program for all of 2024. This stock is a gem
👍️0
ShadowDiviner72 ShadowDiviner72 7 months ago
New PR, and data release shows that Endoxifen does not only stop the tumor from growing...

It even shows that it eliminates the tumor !!!!!! They cured a patient from breast cancer by taking a simple pill during 6 months!

INCREDIBLE
👍️0
glenn1919 glenn1919 8 months ago
ATOS...........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Joeyohso Joeyohso 8 months ago
Why the dump today? I was able to grab some at 1.65
👍️0
Monksdream Monksdream 8 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 8 months ago
ATOS new 52 hi
👍️0
Monksdream Monksdream 8 months ago
ATOS 10Q due 4/5
👍️0
Monksdream Monksdream 8 months ago
ATOS new 52 hi
👍️0
glenn1919 glenn1919 8 months ago
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
ATOS..LEVEL 2 LOOKING VERY NICE IN PRE
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
ATOS...GET READY TO RUMBLE...WE ARE LOCKED IN AND LOADED TO 1.73
👍️0
glenn1919 glenn1919 8 months ago
ATOS.............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 8 months ago
ATOS.........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 9 months ago
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ATOS................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Birdbrain Ideas Birdbrain Ideas 1 year ago
There hasn't been a post on this board in six weeks. If these Stage 2 trials turn out well, this board will light up along with the share price.
👍️0
Laster Laster 1 year ago
I loved that wall at $1.04 yesterday. It was calling my name. I was too slow.
Then it was taken out. I wasn’t too upset because….
I was lucky enough for another wall at $1.05 that I helped take out. Then boom.
Chart looked good. News good. Repurchase plan news excellent.
What’s not to like.
Hope to see if move back above $2.
Good luck.
👍️0
tw0122 tw0122 1 year ago
Looking good. Hidden gem not any longer
👍️0
killrEngineer killrEngineer 1 year ago
Wow. No comments?
10 million share repurchase announcement yesterday and study enrollment announcement today.
👍️0
DrJinx DrJinx 2 years ago
This aged like milk. How's that priming for a big run up working out for you? Maybe someday people will realize the company is smoke and mirrors. Keep in mind your CEO is old as F, he dies... this thing tanks even harder.
👍️0
Engle1488 Engle1488 2 years ago
We are primed for a big run up people. In at 1.04
👍️0
Agreed Agreed 2 years ago
The market cap is less than their holdings in cash...clearly undervalued.
👍️0
Agreed Agreed 3 years ago
Insider buying by CEO and CFO, new patent protections...looking promising.
👍️0
DollarSquad DollarSquad 3 years ago
Yes. You likely lost a lot of money. This investment is worthless. RMSL
👍️0
4MVault 4MVault 3 years ago
Did something just happen?
👍️0
slugo1 slugo1 3 years ago
Looking for bottom here
👍️0
ttottip ttottip 3 years ago
Yes, very soon. This will reverse the trend.
👍️0
slugo1 slugo1 3 years ago
Soon
👍️0
ttottip ttottip 3 years ago
Soon the 2.5's , 2.6's .....
👍️0
slugo1 slugo1 3 years ago
Yes
👍️0
ttottip ttottip 3 years ago
The 2.6's on the horizon.
👍️0
slugo1 slugo1 3 years ago
That's one of the things I like about them Also there should be some updates coming
👍️0
ttottip ttottip 3 years ago
140 millions of dollars cash? ATOS can do great things with this money.
👍️0
slugo1 slugo1 3 years ago
Nice buy worth alot when this hits $10.00
👍️0
ttottip ttottip 3 years ago
Almost 36,000 shares buy at 2.49.
👍️0
DrHarleyboy DrHarleyboy 3 years ago
Good Old "Blue Sky Breakout"././//./..//.///.././..////
👍️0

Your Recent History

NASDAQ
ATOS
Atossa Therapeutics
NASDAQ
ALGS
Aligos Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved